Clinical Trial Update: Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab plus capecitabine (Xeloda) in patients with untreated metastatic colorectal cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Translational Oncology Research International | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-02-06